RUBY · Rubius Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $0 | $0 | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | $24.23M | $33.00M | $38.30M | - | $38.01M | $36.07M | $27.68M | - | $28.21M |
| SG&A | - | $7.30M | $9.91M | $12.56M | - | $12.04M | $13.85M | $13.24M | - | $11.98M |
| Total Operating Expenses | - | $61.58M | $42.91M | $50.86M | - | $50.05M | $49.92M | $40.92M | - | $40.19M |
| D&A | - | - | - | $1.56M | - | - | - | $1.50M | - | - |
| Operating Income | - | ($61.58M) | ($42.91M) | ($50.86M) | - | ($50.05M) | ($49.92M) | ($40.92M) | - | ($40.19M) |
| Interest Expense | - | $1.74M | $1.63M | $1.63M | - | $1.71M | $1.31M | $1.75M | - | $1.17M |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | ($62.87M) | ($44.24M) | ($52.41M) | - | ($49.02M) | ($50.18M) | ($42.33M) | - | ($40.85M) |
| EPS - Basic | - | ($0.70) | ($0.49) | - | - | - | - | - | - | - |
| EPS - Diluted | - | ($0.55) | ($0.49) | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $14.87M | $103.88M | $62.21M | $98.10M | $225.85M | $264.02M | $283.23M | $288.09M | $91.17M | $75.17M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.23M | $8.72M | $12.44M | $12.08M | $11.57M | $8.49M | $5.18M | $4.81M | $5.48M | $9.13M |
| Current Assets | $20.20M | $110.82M | $143.49M | $180.04M | $229.82M | $270.47M | $304.29M | $336.26M | $181.51M | $214.36M |
| Total Assets | $23.07M | $170.70M | $229.08M | $267.12M | $318.02M | $361.06M | $396.08M | $430.23M | $277.79M | $312.36M |
| Current Liabilities | $7.94M | $32.62M | $30.99M | $28.92M | $34.66M | $30.93M | $25.10M | $30.67M | $27.84M | $30.00M |
| Long-term Debt | $0 | $76.83M | $76.60M | $76.38M | $76.15M | $75.93M | $75.70M | $66.26M | $74.94M | $74.83M |
| Total Liabilities | $7.94M | $134.11M | $133.54M | $132.47M | $139.24M | $136.86M | $131.97M | $129.25M | $136.23M | $139.25M |
| Stockholders' Equity | $15.13M | $36.59M | $95.54M | $134.65M | $178.78M | $224.21M | $264.11M | $300.98M | $141.56M | $173.12M |
| Retained Earnings | ($856.68M) | ($836.54M) | ($773.67M) | ($729.43M) | ($677.02M) | ($622.00M) | ($572.98M) | ($522.80M) | ($480.47M) | ($439.93M) |
Cash Flow
| Line item | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($47.13M) | - | - | - | ($38.74M) | - | - |
| Investing Cash Flow | - | - | - | ($80.85M) | - | - | - | $41.75M | - | - |
| Financing Cash Flow | - | - | - | $76.0K | - | - | - | $193.91M | - | - |
| CapEx | - | - | - | $2.40M | - | - | - | $748.0K | - | - |
| Free Cash Flow | - | - | - | ($49.54M) | - | - | - | ($39.49M) | - | - |
Ratios
| Metric | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | 0.95 | - | - | - | 0.93 | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | -36.8% | -19.3% | -19.6% | - | -13.6% | -12.7% | -9.8% | - | -13.1% |
| Return on equity | - | -171.8% | -46.3% | -38.9% | - | -21.9% | -19.0% | -14.1% | - | -23.6% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.54 | 3.40 | 4.63 | 6.23 | 6.63 | 8.74 | 12.12 | 10.96 | 6.52 | 7.15 |
| Quick ratio | 2.54 | 3.40 | 4.63 | 6.23 | 6.63 | 8.74 | 12.12 | 10.96 | 6.52 | 7.15 |
| Cash ratio | 1.87 | 3.18 | 2.01 | 3.39 | 6.52 | 8.53 | 11.28 | 9.39 | 3.27 | 2.51 |
| Leverage | ||||||||||
| Debt / Equity | 0.00 | 2.10 | 0.80 | 0.57 | 0.43 | 0.34 | 0.29 | 0.22 | 0.53 | 0.43 |
| Debt / Assets | 0.00 | 0.45 | 0.33 | 0.29 | 0.24 | 0.21 | 0.19 | 0.15 | 0.27 | 0.24 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | -35.5x | -26.3x | -31.2x | - | -29.3x | -38.1x | -23.4x | - | -34.2x |
| Equity multiplier | 1.52 | 4.67 | 2.40 | 1.98 | 1.78 | 1.61 | 1.50 | 1.43 | 1.96 | 1.80 |
| Liabilities / Assets | 0.34 | 0.79 | 0.58 | 0.50 | 0.44 | 0.38 | 0.33 | 0.30 | 0.49 | 0.45 |
| Efficiency | ||||||||||
| Asset turnover | - | 0.00 | 0.00 | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | -23.0% | 14.1% | -24.3% | - | -24.5% | -32.4% | 16.2% | - | 17.1% |
| Net income growth (YoY) | - | -28.3% | 11.8% | -23.8% | - | -20.0% | -32.6% | 12.7% | - | 13.1% |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | -25.5% | - | - | - | 7.9% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -91.5% | -83.7% | -63.8% | -55.3% | 26.3% | 29.5% | 28.5% | 28.0% | -48.4% | -43.7% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Rubius Therapeutics against the 5 most active filers in the same SIC group.